# SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06980272/  
OnCo record `nct06980272` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing PF-08634404 in non-small-cell lung cancer, now recruiting.

## Summary

SSGJ-707 in Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06980272, led by Shenyang Sunshine Pharmaceutical, and recruiting on the registry. Official title: A Randomised Controlled, Multi-centre Phase III Clinical Trial of SSGJ-707 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer. Planned enrolment is 420 participants (estimated). The study started in 2025-06-20 and primary completion is expected in 2026-07-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06980272
- Phase: 3
- Setting: A Randomized Controlled, Multi-center Phase III Clinical Trial of SSGJ-707 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Shenyang Sunshine Pharmaceutical
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT06980272: https://clinicaltrials.gov/study/NCT06980272

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [3SBio](https://onco.cc/companies/3sbio/)

---
JSON: https://onco.cc/api/v1/entities/nct06980272.json